دورية أكاديمية
أعرض في EDS

Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.

التفاصيل البيبلوغرافية
العنوان: Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.
المؤلفون: Lee DJ; Department of Medicine, Massachusetts General Hospital, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., El-Khoury H; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Tramontano AC; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA., Alberge JB; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Davis MI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Horowitz E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA., Sakrikar D; The Binding Site Inc, Rochester, MN., Barnidge D; The Binding Site Inc, Rochester, MN., Perkins MC; The Binding Site Group Ltd, Birmingham, United Kingdom., Harding S; The Binding Site Group Ltd, Birmingham, United Kingdom., Mucci L; Harvard T.H. Chan School of Public Health, Boston, MA., Rebbeck TR; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.; Harvard T.H. Chan School of Public Health, Boston, MA., Ghobrial IM; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Marinac CR; Harvard Medical School, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
المصدر: Blood advances [Blood Adv] 2024 Apr 09; Vol. 8 (7), pp. 1737-1746.
نوع المنشور: Clinical Trial; Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Society of Hematology, [2016]-
مواضيع طبية MeSH: Monoclonal Gammopathy of Undetermined Significance*/diagnosis , Monoclonal Gammopathy of Undetermined Significance*/epidemiology , Monoclonal Gammopathy of Undetermined Significance*/complications , Multiple Myeloma*/diagnosis , Multiple Myeloma*/epidemiology , Multiple Myeloma*/etiology, Humans ; Obesity/complications ; Obesity/diagnosis ; Obesity/epidemiology ; Risk Factors
مستخلص: Abstract: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition of multiple myeloma with few known risk factors. The emergence of mass spectrometry (MS) for the detection of MGUS has provided new opportunities to evaluate its risk factors. In total, 2628 individuals at elevated risk for multiple myeloma were enrolled in a screening study and completed an exposure survey (PROMISE trial). Participant samples were screened by MS, and monoclonal proteins (M-proteins) with concentrations of ≥0.2 g/L were categorized as MS-MGUS. Multivariable logistic models evaluated associations between exposures and MS outcomes. Compared with normal weight (body mass index [BMI] of 18.5 to <25 kg/m2), obesity (BMI of ≥30 kg/m2) was associated with MS-MGUS, adjusting for age, sex, Black race, education, and income (odds ratio [OR], 1.73; 95% confidence interval [CI], 1.21-2.47; P = .003). High physical activity (≥73.5 metabolic equivalent of task (MET)-hours per week vs <10.5 MET-hours per week) had a decreased likelihood of MS-MGUS (OR, 0.45, 95% CI, 0.24-0.80; P = .009), whereas heavy smoking and short sleep had increased likelihood of MS-MGUS (>30 pack-years vs never smoker: OR, 2.19; 95% CI, 1.24-3.74; P = .005, and sleep <6 vs ≥6 hours per day: OR, 2.11; 95% CI, 1.26-3.42; P = .003). In the analysis of all MS-detected monoclonal gammopathies, which are inclusive of M-proteins with concentrations of <0.2 g/L, elevated BMI and smoking were associated with all MS-positive cases. Findings suggest MS-detected monoclonal gammopathies are associated with a broader range of modifiable risk factors than what has been previously identified. This trial was registered at www.clinicaltrials.gov as #NCT03689595.
(© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: Br J Cancer. 2018 Apr;118(7):1013-1019. (PMID: 29527008)
PLoS One. 2014 Apr 29;9(4):e96406. (PMID: 24781037)
Nat Rev Cancer. 2008 Mar;8(3):205-11. (PMID: 18235448)
JAMA Oncol. 2015 Jun;1(3):342-9. (PMID: 26181184)
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):833-46. (PMID: 24633143)
Am J Hypertens. 2013 Jul;26(7):903-11. (PMID: 23564028)
N Engl J Med. 2002 Feb 21;346(8):564-9. (PMID: 11856795)
Lancet Haematol. 2022 May;9(5):e340-e349. (PMID: 35344689)
Blood Cancer J. 2022 Apr 1;12(4):51. (PMID: 35365600)
Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):631-4. (PMID: 25538226)
Blood Adv. 2022 Jun 28;6(12):3746-3750. (PMID: 35316833)
Ann Hematol. 2021 Apr;100(4):855-863. (PMID: 33416902)
Blood Cancer J. 2019 Dec 13;9(12):102. (PMID: 31836698)
Bone Marrow Transplant. 2014 Aug;49(8):1009-15. (PMID: 24820216)
Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504. (PMID: 10993420)
Blood Cancer J. 2022 Apr 19;12(4):67. (PMID: 35440099)
Clin Chest Med. 2022 Jun;43(2):319-336. (PMID: 35659028)
Front Endocrinol (Lausanne). 2016 Jun 17;7:67. (PMID: 27379019)
Blood Cancer J. 2020 Feb 17;10(2):19. (PMID: 32066732)
Blood. 2010 Aug 19;116(7):1056-9. (PMID: 20421448)
Sleep Med Rev. 2021 Apr;56:101409. (PMID: 33333427)
Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2192-2198. (PMID: 36126958)
Cancer Prev Res (Phila). 2021 Jan;14(1):41-54. (PMID: 32928877)
Lancet. 2022 Aug 20;400(10352):563-591. (PMID: 35988567)
Am J Hematol. 2016 Jun;91(6):581-4. (PMID: 26953904)
N Engl J Med. 2016 Aug 25;375(8):794-8. (PMID: 27557308)
Haematologica. 2014 Jun;99(6):984-96. (PMID: 24658815)
Am J Public Health. 2016 Sep;106(9):1573-81. (PMID: 27459450)
Blood Adv. 2017 Nov 01;1(24):2186-2192. (PMID: 29296866)
BMJ. 2020 Jan 8;368:l6669. (PMID: 31915124)
Leukemia. 2010 Jun;24(6):1121-7. (PMID: 20410922)
معلومات مُعتمدة: F32 CA220859 United States CA NCI NIH HHS; K22 CA251648 United States CA NCI NIH HHS
سلسلة جزيئية: ClinicalTrials.gov NCT03689595
تواريخ الأحداث: Date Created: 20240111 Date Completed: 20240401 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC10997907
DOI: 10.1182/bloodadvances.2023010843
PMID: 38212245
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-9537
DOI:10.1182/bloodadvances.2023010843